Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Enterprise Value for the quarter that ended in Mar. 2026 was E£6,041 Mil.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£527 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBIT Related Terms
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBIT Chart
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend
Jun24
Jun25
EV-to-EBIT
1.89
9.83
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile EV-to-EBIT vs Drug Manufacturers Industry
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Enterprise Value is E£19,902 Mil.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£527 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a EV-to-EBIT of 37.78 as of Aug. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. This is 171% above median its historical median of 13.92. Over the past decade, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EV-to-EBIT has ranged from 9.79 to 41.36. According to the industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #545 out of 691 companies in the Drug Manufacturers industry, placing it in the top 78.9%.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EV-to-EBIT too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EV-to-EBIT of 37.78 is 171% above median its 10-year median of 13.92. Over the past 10 years, this metric has ranged from a low of 9.79 to a high of 41.36. The Drug Manufacturers industry median EV-to-EBIT is 15.71. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 37.78 is 140.5% above this industry median. Based on the distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #545 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Scoreâ„¢ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile ranks #545 out of 691 companies for EV-to-EBIT. This places El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile in the lower half of its industry. The industry median EV-to-EBIT is 15.71. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's value of 37.78 is 140.5% above this benchmark. Historically, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's own EV-to-EBIT has ranged from 9.79 to 41.36 over the past decade. While the company's 10-year median is 13.92 vs. the industry median of 15.71, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.71, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EV-to-EBIT of 37.78 is 140.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current EV-to-EBIT is 37.78, which is 171% above median its own 10-year median of 13.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current EV-to-EBIT of 37.78. The current EV-to-EBIT is 37.78, which is 171% above median its 10-year median of 13.92 and 140.5% above the Drug Manufacturers industry median of 15.71. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current EV-to-EBIT is 37.78 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score
Get the complete analysis for CAI:NIPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:NIPH has been successfully added to your 
